An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Trial Details

NCT ID

NCT06560112

Phase

PHASE2

Sponsor

Akeso

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• AK104
• AK112
• Chemotherapy

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• Signs the written informed consent form.
• Female participants who are at least 18 years of age on the day of signing informed consent with.
• ECOG of 0 or 1.
• Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.